IVDR Consulting 2026: Key Developments, Milestones and Compliance Strategy

Key Takeaways

• Four EUDAMED modules became mandatory on 28 May 2026, introducing new operational compliance requirements for manufacturers
• Class C legacy devices were required to lodge a formal application with a notified body by 26 May 2026, with a written agreement required by 26 September 2026
• Commission Implementing Regulation (EU) 2026/977 introduced maximum timelines for conformity assessment stages, improving predictability for manufacturers
• IVDR performance evaluation is an ongoing lifecycle process covering scientific validity, analytical performance, and clinical performance
• Post-Market Performance Follow-Up (PMPF) and ongoing literature surveillance are required components of lifecycle evidence management
• The European Commission proposed a targeted revision of the MDR and IVDR in December 2025, though these remain proposals and are not yet current requirements
• AI-enabled IVDs must consider both the IVDR and applicable AI Act requirements under Regulation (EU) 2026/1744
• Technical documentation must remain internally consistent throughout the device lifecycle to withstand Notified Body scrutiny

Table of Contents

1. Direct Answer: What Is IVDR and What Has Changed in 2026?
2. Why It Matters: The IVDR Compliance Landscape in 2026
3. How It Works: IVDR Classification, Performance Evaluation and Lifecycle Compliance
4. Common Mistakes: Where Manufacturers Face IVDR Challenges
5. Best Practices: What Effective IVDR Consulting Looks Like
6. Comparison Table
7. Checklist
8. Definitions
9. Expert Perspective
10. FAQ
11. References
12. Related Resources
13. Call to Action

Direct Answer: What Is IVDR and What Has Changed in 2026?

The IVDR (Regulation (EU) 2017/746) is the EU regulatory framework governing in vitro diagnostic medical devices. It replaced the previous In Vitro Diagnostic Directive (IVDD) and introduced significantly more stringent requirements for device classification, performance evaluation, notified body involvement, and post-market surveillance.

In 2026, several important implementation milestones have changed the practical focus of IVDR consulting. Four EUDAMED modules became mandatory on 28 May 2026. Class C legacy device transitional deadlines required immediate notified body engagement. Commission Implementing Regulation (EU) 2026/977 introduced maximum timelines for conformity assessment stages. Harmonised standards were updated twice. And the European Commission proposed a targeted revision of the MDR and IVDR framework.

These developments mean that IVDR compliance in 2026 is a complex, multi-layered obligation that requires active management rather than a one-time exercise.

Why It Matters: The IVDR Compliance Landscape in 2026

IVDR in 2026: Key Milestones

Several important IVDR implementation milestones fall in 2026, making this a particularly important year for manufacturers navigating the transition.

26 May 2026: Class C legacy devices — deadline to lodge a formal application with a notified body (subject to the transitional conditions established under Regulation (EU) 2024/1860)

28 May 2026: Four EUDAMED modules become mandatory

26 September 2026: Class C legacy devices — deadline for a written agreement with a notified body (subject to the transitional conditions established under Regulation (EU) 2024/1860)

31 December 2028: End of the extended transition period for eligible Class C legacy devices (subject to the transitional conditions established under Regulation (EU) 2024/1860)

EUDAMED Becomes Mandatory

One of the most significant operational changes in 2026 was the introduction of mandatory use of the first four functional modules of EUDAMED on 28 May 2026. These include Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance.

Mandatory EUDAMED use has practical implications for manufacturers. Manufacturers need processes to ensure that required device, economic operator, and certification information is accurate, complete, and maintained appropriately within the system. For IVDR consultants, EUDAMED now needs to form part of routine compliance and market-access planning.

Transitional Deadlines Require Immediate Regulatory Planning

The extended IVDR transitional periods have provided manufacturers with additional time to transition eligible legacy devices, but these extensions are conditional and include specific regulatory milestones. For eligible Class C legacy devices, manufacturers were required to lodge a formal application with a notified body by 26 May 2026. A written agreement between the manufacturer and notified body must then be in place by 26 September 2026 for the applicable extended transition period, which may allow qualifying Class C devices to remain on the market until 31 December 2028.

The extended transition periods do not remove the need for timely IVDR preparation. Manufacturers need to understand whether their devices qualify for the transitional provisions, whether the applicable conditions have been satisfied, and how the remaining transition period affects their regulatory and market-access strategy.

Notified Body and Conformity Assessment Expectations Continue to Evolve

Commission Implementing Regulation (EU) 2026/977, adopted in May 2026, introduced uniform procedural requirements for conformity assessment activities performed by notified bodies under the MDR and IVDR. The Regulation establishes maximum timelines for several stages of conformity assessment: 30 days for application review and contract signature, 120 days for quality management system auditing, 90 days for product verification, and 20 days for the final decision and certification. These requirements are intended to improve consistency and predictability across notified body conformity assessment.

Harmonised Standards Continue to Evolve

Harmonised standards supporting the IVDR framework have continued to change in 2026. Commission Implementing Decision (EU) 2026/197 updated the IVDR list in January to include revised standards relating to sterilization of health care products and information supplied by the manufacturer, including labelling. A further update in June, Implementing Decision (EU) 2026/1313, addressed the harmonised standard for symbols used with information supplied by manufacturers. Conformity with applicable harmonised standards referenced in the Official Journal can provide a presumption of conformity with the corresponding IVDR requirements covered by those standards.

How It Works: IVDR Classification, Performance Evaluation and Lifecycle Compliance

What Makes IVDR Consulting Different?

The IVDR introduced several fundamental changes to the regulation of IVDs in the European Union. These changes affect how a device is classified, the regulatory pathway it follows, the evidence required to support it, and the level of external regulatory oversight involved.

Identification of Device Class

One of the most important changes introduced under the IVDR is the shift toward a risk-based classification system. IVDs are classified as Class A, B, C, or D according to their intended purpose and associated risk, with Class A representing the lowest-risk devices and Class D the highest. Correct classification is important because it determines the regulatory pathway that a manufacturer should follow, including the applicable conformity assessment procedure and the level of notified body involvement.

Greater Notified Body Involvement

Under the IVDR, many IVDs that could previously be self-certified now require notified body involvement as part of their conformity assessment before being placed on the EU market. Manufacturers need to determine whether notified body involvement is required for their device, select an appropriately designated notified body, prepare the necessary technical documentation and performance evidence, and account for the conformity assessment process within their regulatory timelines.

Performance Evaluation Is Central to IVDR Consulting

Under the IVDR, performance evaluation is an ongoing process used to assess and analyse data relating to the scientific validity, analytical performance, and clinical performance of a device. Together, these three elements provide the evidence needed to support the device’s intended purpose and performance claims.

Scientific validity establishes whether there is a scientifically supported association between an analyte or marker and a particular clinical condition or physiological state. Evidence supporting scientific validity may come from sources such as peer-reviewed scientific literature, relevant studies, expert consensus, or other appropriate scientific evidence.

Analytical performance considers how reliably and accurately the device detects or measures the analyte it is designed to assess. Depending on the type and intended purpose of the IVD, this may include characteristics such as accuracy, precision, analytical sensitivity and specificity, measuring range, detection limits, and potential interference.

Clinical performance considers whether the results produced by the device are appropriately correlated with a particular clinical condition or physiological or pathological process in the intended population and setting. Clinical performance evidence must remain consistent with the device’s intended purpose, target population, claims, and overall benefit-risk profile.

Scientific validity, analytical performance, and clinical performance are closely connected. Combined, these three elements form the foundation of the manufacturer’s performance evaluation, which is documented in the Performance Evaluation Report (PER). Performance evaluation does not end once the device has completed conformity assessment. As new evidence emerges during post-market use, manufacturers need to consider whether it affects the existing performance evaluation and update the PER where appropriate.

IVDR Compliance Is a Lifecycle Process

Achieving conformity assessment does not mark the end of a manufacturer’s IVDR responsibilities. Once an IVD is placed on the market, manufacturers must continue to collect and evaluate information about its safety and performance throughout the device lifecycle.

Post-Market Performance Follow-Up (PMPF) is a continuous process used to proactively collect and evaluate performance data from the use of an IVD after it has been placed on the market. It helps manufacturers confirm that the device continues to perform as intended, identify previously unknown risks or limitations, and detect changes that could affect the device’s benefit-risk profile or performance.

Ongoing literature surveillance is another important component of lifecycle evidence management. Systematic review of current scientific and clinical literature helps manufacturers identify new evidence relating to the device, its analyte or marker, comparable or alternative technologies, emerging risks, and changes in the accepted state of the art. Together, PMPF and ongoing literature surveillance create a continuous evidence cycle in which new information is collected, evaluated, and used to update the performance evaluation.

Regulatory Reform and Developments to Watch

In December 2025, the European Commission proposed a targeted revision of the MDR and IVDR intended to simplify certain requirements, reduce regulatory burden, and improve the efficiency of the existing system. These changes remain proposals and should not be treated as current IVDR requirements unless and until they are adopted through the EU legislative process.

The proposal would remove the standard five-year maximum certificate validity period, replacing it with periodic reviews proportionate to device risk. For Class B and C IVDs, the proposed changes would reduce the extent of notified body technical documentation assessment through representative-device sampling. A legal basis for structured dialogue between manufacturers and notified bodies before and after submission is also proposed.

The regulatory landscape for AI-enabled IVDs also continued to develop in 2026. The Digital Omnibus on AI, adopted as Regulation (EU) 2026/1744, introduced measures intended to simplify implementation of the AI Act and clarify its interaction with other EU legislation. Manufacturers developing AI-enabled IVDs need to consider both the IVDR and applicable AI Act requirements when planning their regulatory strategy.

Technical Documentation Has to Remain Aligned

Accurate and internally consistent technical documentation is essential to demonstrating IVDR compliance. Inconsistencies can arise between different sections of the technical file, particularly when information is updated by different teams or at different stages of the device lifecycle. Even relatively small discrepancies can create questions during regulatory review if the device’s intended purpose, supporting evidence, claims, or regulatory strategy are not presented consistently.

Common Mistakes: Where Manufacturers Face IVDR Challenges

Incorrect device classification

An incorrect classification has downstream implications for technical documentation, performance evidence, conformity assessment, and the manufacturer’s overall approach to IVDR compliance. Classification should be established early and reviewed if the intended purpose changes.

Underestimating the transitional timeline

The extended transition periods do not remove the need for timely IVDR preparation. Manufacturers who assume they have more time than the conditional transitional provisions allow risk missing notified body application and agreement deadlines, with direct consequences for continued market access.

Treating performance evaluation as a one-time exercise

Performance evaluation does not end at conformity assessment. Manufacturers who fail to maintain the Performance Evaluation Report in response to new post-market evidence, PMPF findings, or literature surveillance results risk having outdated documentation identified during Notified Body surveillance audits.

EUDAMED non-compliance

With four modules now mandatory, manufacturers who have not established processes for accurate and maintained EUDAMED registration risk compliance gaps that are directly visible to market surveillance authorities.

Technical documentation inconsistencies

Where different sections of the technical file are updated at different times by different teams, inconsistencies emerge between the intended purpose, performance claims, and supporting evidence. These inconsistencies are among the most common findings during Notified Body assessment.

Failing to monitor regulatory developments

The IVDR landscape continues to evolve through new harmonised standards, implementing regulations, and proposed legislative changes. Manufacturers who do not maintain active regulatory surveillance risk being caught out by changes that affect their existing compliance documentation or strategy.

Best Practices: What Effective IVDR Consulting Looks Like

Effective IVDR consulting requires specific knowledge of IVD regulation and an understanding of how its requirements interact across the device lifecycle. Manufacturers should choose an experienced consultant with proven regulatory knowledge relevant to their device class, intended purpose, and performance evidence requirements.

IVDR expertise needs to remain current. Regulatory requirements and their implementation continue to evolve, making ongoing surveillance of new guidance, regulatory developments, and applicable deadlines an important part of effective IVDR consulting. A strong consulting partner identifies relevant changes early and translates them into practical regulatory action.

IVDR consulting can extend across the entire device lifecycle, covering classification, performance evaluation strategy, notified body readiness, EUDAMED compliance, PMPF and literature surveillance programme design, technical documentation review, and regulatory reform monitoring.

Pre-market performance evaluation and post-market surveillance need to remain connected throughout the device lifecycle, with evidence generated after market entry feeding back into the manufacturer’s regulatory documentation and Performance Evaluation Report.

Comparison Table: IVDD vs IVDR

Checklist: IVDR Compliance Readiness in 2026

Classification and regulatory pathway:

• Device classification confirmed as Class A, B, C, or D under IVDR risk-based rules
• Regulatory pathway and notified body involvement requirements established
• Classification reviewed against current intended purpose and any changes to device design or intended use

Transitional provisions (Class C legacy devices):

• Eligibility for transitional provisions under Regulation (EU) 2024/1860 confirmed
• Formal application lodged with a notified body by 26 May 2026
• Written agreement with notified body in place by 26 September 2026
• Transition period strategy and 31 December 2028 deadline factored into regulatory planning

EUDAMED compliance:

• Actor registration completed and maintained
• UDI/device registration accurate and current
• Notified body certificate information reflected correctly
• Market surveillance module obligations understood and addressed

Performance evaluation:

• Scientific validity evidence identified and evaluated
• Analytical performance data assessed against applicable requirements
• Clinical performance evidence consistent with intended purpose and claims
• Performance Evaluation Report current and updated in response to new evidence

Post-market lifecycle:

• PMPF programme established and generating data
• Literature surveillance conducted regularly using structured methodology
• Post-market findings reflected in updated Performance Evaluation Report
• Post-market surveillance system active and integrated with performance evaluation

Technical documentation:

• Intended purpose, performance claims, and supporting evidence consistent across the technical file
• Harmonised standards reviewed against current applicable versions
• Technical documentation updated to reflect any changes to device, evidence, or regulatory requirements

Regulatory monitoring:

• Commission proposal for MDR/IVDR revision being monitored
• AI Act implications assessed for AI-enabled IVDs
• Harmonised standards updates reviewed and assessed for impact

Definitions

IVDR
Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The EU regulatory framework governing IVDs placed on the European market, replacing the previous In Vitro Diagnostic Directive (IVDD).

Performance Evaluation Report (PER)
The document in which manufacturers compile, evaluate, and document the evidence supporting the scientific validity, analytical performance, and clinical performance of an IVD. The PER must be maintained and updated throughout the device lifecycle.

Scientific validity
The scientifically supported association between an analyte or marker and a particular clinical condition or physiological state. Scientific validity must be established before analytical and clinical performance can be meaningfully assessed.

Analytical performance
How reliably and accurately a device detects or measures the analyte it is designed to assess. Includes accuracy, precision, analytical sensitivity and specificity, measuring range, detection limits, and potential interference.

Clinical performance
The ability of a device to produce results that are appropriately correlated with a particular clinical condition or physiological or pathological process in the intended population and setting.

Post-Market Performance Follow-Up (PMPF)
The continuous process of proactively collecting and evaluating performance data from the use of an IVD after it has been placed on the market. PMPF findings must feed back into the Performance Evaluation Report.

EUDAMED
The European Database on Medical Devices. A central EU database for the registration and surveillance of medical devices and IVDs. Four modules became mandatory under the IVDR on 28 May 2026.

Transitional provisions
Conditional arrangements established under Regulation (EU) 2024/1860 allowing eligible IVDD-certified devices to remain on the market during a defined transition period while manufacturers work toward full IVDR compliance.

Harmonised standards
Standards developed by European standardisation bodies and referenced in the Official Journal of the EU. Conformity with applicable harmonised standards provides a presumption of conformity with the corresponding IVDR requirements covered by those standards.

Expert Perspective

The most consistent challenge in IVDR consulting in 2026 is not a lack of awareness of the requirements. It is the gap between understanding what is required and having the processes in place to meet it continuously throughout the device lifecycle. Performance evaluation is where this gap is most visible. Manufacturers who completed their Performance Evaluation Report for conformity assessment and then treated it as a static document are now discovering that post-market evidence, PMPF findings, and literature surveillance have generated data that should have been reflected in updates. The IVDR is explicit that performance evaluation is ongoing. The practical implication is that the PER is a living document, and the systems that feed it need to generate and integrate data continuously, not periodically.

Frequently Asked Questions

What is IVDR and how does it differ from IVDD?

The IVDR (Regulation (EU) 2017/746) replaced the previous In Vitro Diagnostic Directive (IVDD) and introduced significantly more stringent requirements for IVDs placed on the EU market. Key differences include a risk-based classification system (Class A through D), considerably greater notified body involvement for most device classes, structured performance evaluation requirements covering scientific validity, analytical performance, and clinical performance, and ongoing post-market obligations including PMPF and regular literature surveillance. Manufacturers who previously self-certified under IVDD may now require notified body involvement for the first time.

What are the key IVDR deadlines in 2026?

The most important IVDR milestones in 2026 are the mandatory activation of four EUDAMED modules on 28 May 2026, the Class C legacy device notified body application deadline of 26 May 2026, and the written agreement deadline of 26 September 2026. These transitional provisions are subject to the conditions established under Regulation (EU) 2024/1860. The extended transition period for eligible Class C devices ends on 31 December 2028.

What is IVDR performance evaluation?

IVDR performance evaluation is the ongoing process of assessing and documenting the evidence supporting a device’s scientific validity, analytical performance, and clinical performance. Scientific validity establishes the clinical relevance of the analyte or marker being measured. Analytical performance addresses how accurately and reliably the device measures it. Clinical performance addresses whether results correlate appropriately with the clinical condition in the intended population. All three elements must be documented in the Performance Evaluation Report, which must be updated throughout the device lifecycle as new evidence emerges from PMPF, literature surveillance, and post-market surveillance activities.

What is EUDAMED and what became mandatory in 2026?

EUDAMED is the European Database on Medical Devices, a central EU system for device registration and market surveillance. On 28 May 2026, four EUDAMED modules became mandatory under the IVDR: Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance. Manufacturers are required to ensure that information in these modules is accurate, complete, and maintained appropriately.

What is Post-Market Performance Follow-Up (PMPF)?

PMPF is the continuous process through which manufacturers proactively collect and evaluate performance data from IVDs that have been placed on the market. It helps confirm that the device continues to perform as intended, identify previously unknown risks or limitations, and detect changes that could affect the benefit-risk profile. PMPF findings must feed back into the Performance Evaluation Report and are an important component of demonstrating ongoing IVDR compliance throughout the device lifecycle.

What are the proposed changes to IVDR from the European Commission?

In December 2025, the European Commission proposed a targeted revision of the MDR and IVDR. For the IVDR, key proposals include removing the standard five-year maximum certificate validity period in favour of periodic reviews proportionate to device risk, reducing the extent of notified body technical documentation assessment for Class B and C IVDs through representative-device sampling, and introducing a legal basis for structured dialogue between manufacturers and notified bodies. These remain proposals and are not yet current IVDR requirements. Manufacturers should monitor the legislative process but should not treat proposed changes as applicable until formally adopted.

How does IVDR consulting support manufacturers in 2026?

IVDR consulting supports manufacturers across the full device lifecycle, from classification and performance evaluation strategy through notified body readiness, EUDAMED compliance, PMPF programme design, literature surveillance, technical documentation review, and regulatory reform monitoring. In 2026, with multiple transitional deadlines, mandatory EUDAMED modules, evolving harmonised standards, and proposed legislative changes all in play simultaneously, effective consulting requires active regulatory surveillance and the ability to translate new developments into practical compliance action quickly. For support with post-market surveillance and clinical evidence management as part of your IVDR strategy, Citemeds can help.

References

• Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)
• Regulation (EU) 2024/1860 — IVDR transitional provisions and EUDAMED-related measures
• EUDAMED — European Database on Medical Devices
• Commission Implementing Regulation (EU) 2026/977 — conformity assessment procedural requirements
• Commission Implementing Decision (EU) 2026/197 — harmonised standards under the IVDR
• Commission Implementing Decision (EU) 2026/1313 — harmonised standards under the IVDR
• European Commission proposal for the targeted revision of the MDR and IVDR, December 2025
• Regulation (EU) 2026/1744 — Digital Omnibus on AI

Related Resources

• Post-Market Surveillance Under EU MDR — Building a proactive PMS system aligned with EU MDR and IVDR expectations
• CER Checklist for EU MDR — A practical framework for pre-submission review of Clinical Evaluation Reports
• Why Clinical Evaluation Reports Are Rejected — Common reasons CERs and PERs fail Notified Body review
• EU MDR Literature Review Services — Structured literature surveillance supporting IVDR performance evaluation and PMPF
• PMCF Surveys Solution — Structured post-market follow-up activities supporting ongoing performance evidence
• Medical Device Vigilance — Vigilance monitoring and reporting support
• EU MDR Consulting Services — Expert regulatory support for IVDR compliance and market access strategy
• PRISMA and EU MDR Literature Review — Structured literature review methodology supporting IVDR performance evaluation

Call to Action

If you are managing IVDR compliance in 2026 and need support with performance evaluation, literature surveillance, PMPF programme design, notified body readiness, or technical documentation review, Citemeds can help. Get in touch to discuss your requirements.